

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL				
OMB	3235-			
Number:	0104			
Estimated average	ge			
burden hours pei	r			
response	0.5			

SEC 1473 (7-02)

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)						
1. Name and Address of Reporting Person [*] – Sullivan Lara	2. Date of Event Requiring Statement (Month/Day/Year) 02/27/2019	g 3. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455	02/27/2019	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director10% Owner Officer (giveOther (specify title below)Other (specify			5. If Amendment, Date Original Filed(Month/Day/Year)	
(Street) ROCKVILLE, MD 20850					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reportin Person	
(City) (State) (Zip)	Table I - N	on-Derivati	ive Securitie	es Ben	eficially Owned	
1.Title of Security 2. Amo (Instr. 4) Benefic (Instr. 4) (Instr. 4)		Securities Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Owne	•	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security	2. Date Exercisable		2. Date Exercisable 3. Title and Amount of 4		4.	5.	6. Nature of Indirect	
(Instr. 4)	and Expirati	piration Date Securities Underlying		Conversion	Ownership	Beneficial Ownership		
	(Month/Day/Year)		Derivative Security		or Exercise	Form of	(Instr. 5)	
	(Instr. 4)		Price of	Derivative				
	Date Expiration Derivative Security	Derivative	Security:					
		2	Direct (D)					
		Title	tle of Shares		or Indirect			
				of Shares		(I)		
						(Instr. 5)		

Reporting Owners

Reporting Owner Name / Address		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Sullivan Lara C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	X						

Signatures

/s/Douglas J. Swirsky, as attorney-in-fact for Lara Sullivan	03/01/2019
-**Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

Exhibit List-Exhibit 24 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

REXAHN PHARMACEUTICALS, INC.

SECTION 16 POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints the President and Chief Executive Officer and the Chief Business Officer of Rexahn Pharmaceuticals, Inc. (the "Company"), and each of them, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. *The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.*

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of February 2019.

/s/Lara Sullivan Lara Sullivan